Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 17, Issue 8, Pages 469-481
Publisher
Springer Science and Business Media LLC
Online
2020-07-01
DOI
10.1038/s41585-020-0335-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) James L. Mohler et al. Journal of the National Comprehensive Cancer Network
- Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.
- (2019) Cattrini et al. Cancers
- Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
- (2019) N W Clarke et al. ANNALS OF ONCOLOGY
- Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer
- (2018) Susan G.R. McDuff et al. CANCER
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
- (2018) Liselotte M.S. Boevé et al. EUROPEAN UROLOGY
- Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
- (2018) Xavier Bonfill et al. Cancer Management and Research
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
- (2018) Christopher C Parker et al. LANCET
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
- (2017) K T Nead et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis
- (2017) Kevin T. Nead et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center
- (2016) Vinayak Muralidhar et al. Clinical Genitourinary Cancer
- Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)
- (2016) Claude Schulman et al. EUROPEAN UROLOGY
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details
- (2016) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
- (2016) Gillian M Duchesne et al. LANCET ONCOLOGY
- Erratum: A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients
- (2016) C Jin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Intermittent Androgen Deprivation Therapy—An Important Treatment Option for Prostate Cancer
- (2016) Laurence Klotz et al. JAMA Oncology
- Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer
- (2016) Dawn L. Hershman et al. JAMA Oncology
- Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study
- (2015) Frederik B. Thomsen et al. EUROPEAN JOURNAL OF CANCER
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
- (2015) Paul L. Nguyen et al. EUROPEAN UROLOGY
- Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer
- (2015) Jesse D. Sammon et al. EUROPEAN UROLOGY
- Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer
- (2015) Sean O'Farrell et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer
- (2015) Sindy Magnan et al. JAMA Oncology
- Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer
- (2014) David R. Ziehr et al. BJU INTERNATIONAL
- Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents
- (2014) Julie N. Graff et al. DRUGS & AGING
- Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer
- (2014) Laurent Boccon-Gibod et al. EUROPEAN UROLOGY
- Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
- (2014) Bertrand Tombal et al. LANCET ONCOLOGY
- Evolution of androgen receptor targeted therapy for advanced prostate cancer
- (2014) Yien Ning Sophia Wong et al. Nature Reviews Clinical Oncology
- Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis
- (2014) D Brungs et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis
- (2014) Tobias Engel Ayer Botrel et al. BMC Urology
- Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII
- (2014) Arto J. Salonen et al. Scandinavian Journal of Urology
- A Novel Therapeutic Option for Castration-resistant Prostate Cancer: After or Before Chemotherapy?
- (2013) Alessandro Sciarra et al. EUROPEAN UROLOGY
- Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group
- (2013) Fernando Calais da Silva et al. EUROPEAN UROLOGY
- Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials
- (2013) Saroj Niraula et al. JOURNAL OF CLINICAL ONCOLOGY
- The Neurobiology of Placebo and Nocebo: How Expectations Influence Treatment Outcomes
- (2013) Donald Eknoyan et al. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
- Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
- (2013) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial
- (2013) Paul C. M. S. Verhagen et al. WORLD JOURNAL OF UROLOGY
- Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa)
- (2012) Michael Organ et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial
- (2012) Nicolas Mottet et al. BJU INTERNATIONAL
- Advanced Prostate Cancer Treated with Intermittent or Continuous Androgen Deprivation in the Randomised FinnProstate Study VII: Quality of Life and Adverse Effects
- (2012) Arto J. Salonen et al. EUROPEAN UROLOGY
- Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
- (2012) Giovanni Corona et al. Journal of Sexual Medicine
- The FinnProstate Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer
- (2012) Arto J. Salonen et al. JOURNAL OF UROLOGY
- Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
- (2012) Juanita M. Crook et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Baseline Testosterone on the Efficacy of Degarelix and Leuprolide: Further Insights From A 12-Month, Comparative, Phase III Study in Prostate Cancer Patients
- (2012) Jan-Erik Damber et al. UROLOGY
- Randomized, Double‐Blinded, Placebo‐Controlled Crossover Trial of Treating Erectile Dysfunction with Sildenafil After Radiotherapy and Short‐Term Androgen Deprivation Therapy: Results of RTOG 0215
- (2011) Deborah Watkins Bruner et al. Journal of Sexual Medicine
- Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer
- (2011) Johan F. Langenhuijsen et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
- (2009) Fernando E.C. Calais da Silva et al. EUROPEAN UROLOGY
- The psychosocial aspects of sexual recovery after prostate cancer treatment
- (2009) D Wittmann et al. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
- Age-Related Changes in General and Sexual Health in Middle-Aged and Older Men: Results from the European Male Ageing Study (EMAS)
- (2009) Giovanni Corona et al. Journal of Sexual Medicine
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
- Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer
- (2008) Nicholas Bruchovsky et al. Clinical Genitourinary Cancer
- Continuous versus Six Months a Year Maximal Androgen Blockade in the Management of Prostate Cancer: A Randomised Study
- (2008) Jacques Irani et al. EUROPEAN UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started